Patent Assignment
Reel/Frame 071777/0300
Security Interest
Recorded: 2025-06-27
Pages: 32
Assignor
DYNE THERAPEUTICS, INC.
Executed: 2025-06-27
Assignee
HERCULES CAPITAL, INC., AS AGENT
1 NORTH B STREET, SUITE 2000, SAN MATEO, CALIFORNIA, 94401
Covered Properties
(110)
Muscle Targeting Complexes and Uses Thereof for Treating Myotonic Dystrophy
Application:
19/077,324 →
Publication:
US 2025/0242042
Complexes Comprising An Anti-transferrin Receptor Antibody Linked to An Oligonucleotide And Method Of Delivering Oligonucleotide To A Subject
Patent:
12,370,264 →
Application:
19/066,035 →
Complexes Comprising an Anti-Transferrin Receptor Antibody Linked to an Oligonucleotide and Method of Delivering an Oligonucleotide to a Subject
Application:
19/189,163 →
Publication:
US 2025/0304710
Muscle Targeting Complexes and Uses Thereof for Treating Facioscapulohumeral Muscular Dystrophy
Application:
19/188,423 →
Publication:
US 2025/0270340
Complexes Comprising an Anti-Transferrin Receptor Antibody Linked to an Oligonucleotide and Method of Delivering Oligonucleotide to a Subject
Muscle-Targeting Complexes and Uses Thereof
Application:
17/205,139 →
Publication:
US 2021/0228730
Muscle-Targeting Complexes Comprising an Anti-Transferin Receptor Antibody Linked to an Oligonucleotide and Method of Use Thereof to Induce Exon Skipping
Muscle Targeting Complexes Comprising an Anti-Transferrin Receptor Antibody Linked to an Oligonucleotide and Method of Use Thereof to Treat Duchenne Muscular Dystrophy
Application:
19/231,212 →
Publication:
US 2025/0297024
Methods of Preparing Protein-Oligonucleotide Complexes
Application:
17/616,870 →
Publication:
US 2022/0306685
Muscle Targeting Complexes and Uses Thereof for Modulation of Genes Associated with Muscle Health
Application:
17/791,670 →
Publication:
US 2023/0111147
Muscle Targeting Complexes and Uses Thereof for Treating Myotonic Dystrophy
Application:
17/769,467 →
Publication:
US 2024/0148891
Anti-Transferrin Receptor (Tfr) Antibody and Uses Thereof
Application:
17/796,418 →
Publication:
US 2023/0113823
Anti-Transferrin Receptor (Tfr) Antibody and Uses Thereof
Muscle Targeting Complexes and Uses Thereof for Treating Myotonic Dystrophy
Application:
17/791,681 →
Publication:
US 2023/0144436
Muscle Targeting Complexes and Uses Thereof for Treating Facioscapulohumeral Muscular Dystrophy
Application:
17/791,697 →
Publication:
US 2023/0088865
Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies
Application:
17/791,701 →
Publication:
US 2023/0111212
Muscle-Targeting Complexes and Uses Thereof
Application:
17/791,667 →
Publication:
US 2023/0226212
Muscle-Targeting Complexes and Uses Thereof in Treating Muscle Atrophy
Application:
17/794,768 →
Publication:
US 2023/0117883
Anti-Transferrin Receptor (Tfr) Antibody, Encoding Nucleic Acid Thereof and Method of Use Thereof to Deliver an Oligonucleotide to a Subject
Application:
18/017,167 →
Publication:
US 2023/0256112
Muscle Targeting Complexes and Uses Thereof for Treating Myotonic Dystrophy
Application:
18/017,170 →
Publication:
US 2024/0016952
Muscle Targeting Complexes and Uses Thereof for Treating Facioscapulohumeral Muscular Dystrophy
Application:
18/017,173 →
Publication:
US 2023/0272065
Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies
Application:
18/017,179 →
Publication:
US 2023/0285586
Muscle-Targeting Complexes and Uses Thereof
Application:
18/017,180 →
Publication:
US 2023/0287108
Muscle-Targeting Complexes and Uses Thereof in Treating Muscle Atrophy
Application:
18/017,182 →
Publication:
US 2023/0346966
Methods of Preparing Protein-Oligonucleotide Complexes
Application:
18/024,486 →
Publication:
US 2023/0330562
Antibody-Oligonucleotide Complexes and Uses Thereof
Application:
18/265,065 →
Publication:
US 2024/0100177
Muscle Targeting Complexes and Uses Thereof for Treating Myotonic Dystrophy
Application:
18/270,324 →
Publication:
US 2024/0117356
Muscle Targeting Complexes and Uses Thereof for Treating Facioscapulohumeral Muscular Dystrophy
Application:
18/270,284 →
Publication:
US 2024/0110184
Muscle Targeting Complexes and Uses Thereof for Treating Friedreich's Ataxia
Application:
18/572,321 →
Publication:
US 2025/0099603
Muscle Targeting Complexes and Uses Thereof for Treating Pompe Disease
Application:
18/572,260 →
Publication:
US 2024/0294921
Muscle Targeting Complexes and Uses Thereof for Treating Myotonic Dystrophy
Application:
18/577,468 →
Publication:
US 2024/0325558
Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies
Application:
18/577,452 →
Publication:
US 2024/0368296
Muscle Targeting Complexes and Uses Thereof for Modulation of Genes Associated with Muscle Health
Application:
18/577,382 →
Publication:
US 2024/0382513
Muscle Targeting Complexes and Formulations for Treating Dystrophinopathies
Application:
18/577,348 →
Muscle Targeting Complexes and Formulations for Treating Dystrophinopathies
Application:
18/896,790 →
Publication:
US 2025/0057972
Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies
Application:
18/577,378 →
Publication:
US 2024/0318177
Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies
Application:
18/577,462 →
Publication:
US 2024/0209119
Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies
Application:
18/577,374 →
Publication:
US 2024/0318176
Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies
Application:
18/577,472 →
Publication:
US 2024/0382609
Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies
Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies
Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies
Dosing of Muscle Targeting Complexes for Treating Dystrophinopathies
Application:
18/692,415 →
Publication:
US 2025/0018050
Muscle Targeting Complexes for Treating Dystrophinopathies
Application:
18/706,057 →
Muscle Targeting Complexes for Treating Facioscapulohumeral Muscular Dystrophy
Application:
18/708,815 →
Publication:
US 2025/0025570
Muscle Targeting Complexes and Uses Thereof for Treating Myotonic Dystrophy
Application:
18/856,247 →
Publication:
US 2025/0249116
Muscle Targeting Complexes and Formulations for Treating Myotonic Dystrophy
Muscle Targeting Complexes and Formulations for Treating Myotonic Dystrophy
Muscle Targeting Complexes and Formulations for Treating Myotonic Dystrophy
Application:
18/856,264 →
Dosing of Muscle Targeting Complexes for Treating Myotonic Dystrophy
Application:
18/856,266 →
Publication:
US 2025/0249117
Muscle Targeting Complexes and Uses Thereof for Treating Facioscapulohumeral Muscular Dystrophy
Application:
18/881,012 →
Cns Targeting Complexes and Uses Thereof
Application:
18/881,000 →
Muscle Targeting Complexes and Uses Thereof for Modulation of Genes Associated with Muscle Health
Application:
17/811,332 →
Publication:
US 2023/0203180
Muscle Targeting Complexes and Uses Thereof for Skipping Exon 45 of a Dmd Gene
Application:
19/125,492 →
Agents Useful in Treating Facioscapulohumeral Muscular Dystrophy
Application:
18/102,588 →
Agents Useful in Treating Facioscapulohumeral Muscular Dystrophy
Application:
18/405,477 →
Publication:
US 2024/0401037
Muscle Targeting Complexes and Uses Thereof for Treating Myotonic Dystrophy
Muscle Targeting Complexes and Uses Thereof for Treating Myotonic Dystrophy
Muscle Targeting Complexes and Uses Thereof for Treating Myotonic Dystrophy
A Method of Reducing Expression of DUX4 in a Muscle Cell by Administering an Anti-Transferrin Receptor Antibody Linked to an Oligonucleotide Targeting DUX4
Complex Comprising Anti-Transferrin Receptor Antibody Covalently Linked to an Oligonucleotide That Targets DUX4 Rna
Methods of Intravenouisly Delivering Anti-Transferrin Antibody/Oligonucleotide Complexes to Subjects Having Muscular Dystrophy
Methods of Delivering an Oligonucleotide to a Subject Having Facioscapulohumeral Muscular Dystrophy
Methods of Using Muscle Targeting Complexes to Deliver an Oligonucleotide to a Subject Having Facioscapulohumeral Muscular Dystrophy or a Disease Associated with Muscle Weakness
Muscle-Targeting Complex Comprising an Anti-Transferrin Receptor Antibody Linked to an Oligonucleotide
Methods of Producing Muscle-Targeting Complexes Comprising an Anti-Transferrin Receptor Antibody Linked to an Oligonucleotide
Muscle-Targeting Complexes Comprising an Anti-Transferrin Receptor Antibody Linked to an Oligonucleotide and Methods of Delivering Oligonucleotide to a Subject
Muscle-Targeting Complexes Comprising an Anti-Transferrin Receptor Antibody Linked to an Oligonucleotide
Complexes Comprising an Anti-Transferrin Receptor Antibody Linked to an Oligonucleotide
Complexes Comprising an Anti-Transferrin Receptor Antibody Linked to an Oligonucleotide and Method of Delivering Oligonucleotide to a Subject
Muscle-Targeting Complexes Comprising an Anti-Transferrin Receptor Antibody Linked to an Oligonucleotide
Method of Using an Anti-Transferrin Receptor Antibody to Deliver an Oligonucleotide to a Subject Having Facioscapulohumeral Muscular Dystrophy
Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies
Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies
Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies
Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies
Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies
Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies
Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies
Muscle-Targeting Complexes Comprising an Anti-Transferrin Receptor Antibody Linked to an Oligonucleotide and Methods of Use Thereof to Target Dystrophin and to Treat Duchenne Muscular Dystrophy
Muscle Targeting Complexes Comprising an Anti-Transferrin Receptor Antibody Linked to an Oligonucleotide and Method of Use Thereof to Induce Exon Skipping of Exon 44 of Dystrophin in a Subject
Muscle Targeting Complexes and Formulations for Treating Dystrophinopathies
Anti-Transferrin Receptor Antibody and Uses Thereof
Anti-Transferrin Receptor (Tfr) Antibody and Uses Thereof
Anti-Transferrin Receptor Antibody and Uses Thereof
Muscle Targeting Complexes and Uses Thereof for Treating Myotonic Dystrophy
Muscle Targeting Complexes and Uses Thereof for Treating Facioscapulohumeral Muscular Dystrophy
Muscle Targeting Complexes and Uses Thereof for Treating Facioscapulohumeral Muscular Dystrophy
Muscle Targeting Complexes and Uses Thereof for Treating Facioscapulohumeral Muscular Dystrophy
Muscle Targeting Complexes and Uses Thereof for Treating Facioscapulohumeral Muscular Dystrophy
Muscle Targeting Complexes and Uses Thereof for Treating Facioscapulohumeral Muscular Dystrophy
Muscle Targeting Complexes and Uses Thereof for Treating Myotonic Dystrophy
Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies
Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies
Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies
Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies
Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies
Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies
Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies
Muscle Targeting Complexes and Formulations for Treating Myotonic Dystrophy
Agents Useful in Treating Facioscapulohumeral Muscular Dystrophy
Agents Useful in Treating Facioscapulohumeral Muscular Dystrophy
Agents Useful in Treating Facioscapulohumeral Muscular Dystrophy
Methods and Compositions for Inhibiting Progression of Intramuscular Fibrosis
PCT:
PCT/US2024/017419 ↗
Biomarkers for Repeat Expansion Diseases
PCT:
PCT/US2024/050140 ↗
Muscle Targeting Complexes and Formulations for Treating Facioscapulohumeral Muscular Dystrophy
PCT:
PCT/US2024/061427 ↗
Methods and Compositions for Treating Myotonic Dystrophy
PCT:
PCT/US2025/010126 ↗
Dosing of Muscle Targeting Complexes for Treating Facioscapulohumeral Muscular Dystrophy
PCT:
PCT/US2025/032352 ↗
Title Not Available
PCT:
PCT/US2025/034654 ↗
Biomarkers for Facioscapulohumeral Muscular Dystrophy
PCT:
PCT/US2025/032355 ↗
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Apr 15, 2021
From: SUBRAMANIAN, ROMESH R.; QATANANI, MOHAMMED T.; WEEDEN, TIMOTHY; RHODES, JASON P.
To: DYNE THERAPEUTICS, INC.
Reel/Frame 055928/0080 →
Assignment of Assignor's Interest
Jan 13, 2022
From: WEEDEN, TIMOTHY; SPRING, SEAN
To: DYNE THERAPEUTICS, INC.
Reel/Frame 058638/0477 →
Assignment of Assignor's Interest
Aug 3, 2022
From: SUBRAMANIAN, ROMESH R.; QATANANI, MOHAMMED T.; DESJARDINS, CODY A.; WEEDEN, TIMOTHY
To: DYNE THERAPEUTICS, INC.
Reel/Frame 060703/0688 →
Assignment of Assignor's Interest
Aug 3, 2022
From: KOTELIANSKI, VICTOR
To: DYNE THERAPEUTICS, INC.
Reel/Frame 060703/0728 →
Assignment of Assignor's Interest
Aug 3, 2022
From: BROWN, DUNCAN
To: DYNE THERAPEUTICS, INC.
Reel/Frame 060703/0740 →
Assignment of Assignor's Interest
Aug 3, 2022
From: SUBRAMANIAN, ROMESH R.; QATANANI, MOHAMMED T.; WEEDEN, TIMOTHY; DESJARDINS, CODY A.
To: DYNE THERAPEUTICS, INC.
Reel/Frame 060703/0800 →
Assignment of Assignor's Interest
Aug 3, 2022
From: SUBRAMANIAN, ROMESH R.; QATANANI, MOHAMMED T.; WEEDEN, TIMOTHY; DESJARDINS, CODY A.
To: DYNE THERAPEUTICS, INC.
Reel/Frame 060703/0854 →
Assignment of Assignor's Interest
Aug 4, 2022
From: SUBRAMANIAN, ROMESH R.; QATANANI, MOHAMMED T.; WEEDEN, TIMOTHY; DESJARDINS, CODY A.
To: DYNE THERAPEUTICS, INC.
Reel/Frame 060719/0824 →
Assignment of Assignor's Interest
Aug 4, 2022
From: SUBRAMANIAN, ROMESH R.; QATANANI, MOHAMMED T.; WEEDEN, TIMOTH; DESJARDINS, CODY A.
To: DYNE THERAPEUTICS, INC.
Reel/Frame 060719/0945 →
Assignment of Assignor's Interest
Aug 4, 2022
From: SUBRAMANIAN, ROMESH R.; QATANANI, MOHAMMED T.; WEEDEN, TIMOTHY; DESJARDINS, CODY A.
To: DYNE THERAPEUTICS, INC.
Reel/Frame 060720/0012 →
Corrective Assignment to Correct the the Spelling of the 3RD Inventors First Name Previously Recorded at Reel: 060719 Frame: 0945. Assignor(S) Hereby Confirms the Assignment.
Aug 18, 2022
From: SUBRAMANIAN, ROMESH R.; QATANANI, MOHAMMED T.; WEEDEN, TIMOTHY; DESJARDINS, CODY A.
To: DYNE THERAPEUTICS, INC.
Reel/Frame 061204/0892 →
Assignment of Assignor's Interest
Oct 26, 2022
From: SUBRAMANIAN, ROMESH R.; QATANANI, MOHAMMED T.; WEEDEN, TIMOTHY; DESJARDINS, CODY A.
To: DYNE THERAPEUTICS, INC.
Reel/Frame 061535/0851 →
Assignment of Assignor's Interest
Oct 31, 2022
From: SUBRAMANIAN, ROMESH R.; QATANANI, MOHAMMED T.; WEEDEN, TIMOTHY; DESJARDINS, CODY A.
To: DYNE THERAPEUTICS, INC.
Reel/Frame 061590/0223 →
Assignment of Assignor's Interest
Oct 31, 2022
From: SUBRAMANIAN, ROMESH R.; QATANANI, MOHAMMED T.; WEEDEN, TIMOTHY; DESJARDINS, CODY A.
To: DYNE THERAPEUTICS, INC.
Reel/Frame 061590/0272 →
Assignment of Assignor's Interest
Jan 25, 2023
From: SUBRAMANIAN, ROMESH R.; QATANANI, MOHAMMED T; WEEDEN, TIMOTHY; DESJARDINS, CODY A
To: DYNE THERAPEUTICS, INC.
Reel/Frame 062478/0314 →
Assignment of Assignor's Interest
Jan 25, 2023
From: SUBRAMANIAN, ROMESH R.; QATANANI, MOHAMMED T; WEEDEN, TIMOTHY; DESJARDINS, CODY A
To: DYNE THERAPEUTICS, INC.
Reel/Frame 062478/0410 →
Assignment of Assignor's Interest
Jan 25, 2023
From: SUBRAMANIAN, ROMESH R.; QATANANI, MOHAMMED T; WEEDEN, TIMOTHY; RHODES, JASON P.
To: DYNE THERAPEUTICS, INC.
Reel/Frame 062478/0381 →
Assignment of Assignor's Interest
Jan 25, 2023
From: SUBRAMANIAN, ROMESH R.; QATANANI, MOHAMMED T; WEEDEN, TIMOTHY; DESJARDINS, CODY A
To: DYNE THERAPEUTICS, INC.
Reel/Frame 062478/0339 →
Assignment of Assignor's Interest
Jan 25, 2023
From: SUBRAMANIAN, ROMESH R.; QATANANI, MOHAMMED T; WEEDEN, TIMOTHY; DESJARDINS, CODY A
To: DYNE THERAPEUTICS, INC.
Reel/Frame 062478/0290 →
Assignment of Assignor's Interest
Apr 21, 2023
From: SUBRAMANIAN, ROMESH R.; QATANANI, MOHAMMED T.; WEEDEN, TIMOTHY; DESJARDINS, CODY A.
To: DYNE THERAPEUTICS, INC.
Reel/Frame 063401/0808 →
Assignment of Assignor's Interest
Feb 13, 2025
From: SUBRAMANIAN, ROMESH R.; QATANANI, MOHAMMED T.; WEEDEN, TIMOTHY
To: DYNE THERAPEUTICS, INC.
Reel/Frame 070208/0505 →
Assignment of Assignor's Interest
Mar 4, 2025
From: SUBRAMANIAN, ROMESH R.; QATANANI, MOHAMMED T.; WEEDEN, TIMOTHY; DESJARDINS, CODY A.
To: DYNE THERAPEUTICS, INC.
Reel/Frame 070396/0262 →
Assignment of Assignor's Interest
Apr 16, 2025
From: SUBRAMANIAN, ROMESH R.; QATANANI, MOHAMMED T.; WEEDEN, TIMOTHY; DESJARDINS, CODY A.
To: DYNE THERAPEUTICS, INC.
Reel/Frame 070857/0028 →
Assignment of Assignor's Interest
May 2, 2025
From: SUBRAMANIAN, ROMESH R.; QATANANI, MOHAMMED T.; WEEDEN, TIMOTHY
To: DYNE THERAPEUTICS, INC.
Reel/Frame 071008/0700 →
Assignment of Assignor's Interest
May 2, 2025
From: SUBRAMANIAN, ROMESH R.; QATANANI, MOHAMMED T.; WEEDEN, TIMOTHY; DESJARDINS, CODY A.
To: DYNE THERAPEUTICS, INC.
Reel/Frame 071008/0496 →